COSCIENS Biopharma Inc.

CSCIF Healthcare Biotechnology

COSCIENS Biopharma Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 21.8% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS grew 92.6% and free cash flow grew 113.3%, each against the same quarter a year earlier.

6.49 0.24 +3.84%
Market cap
$8.6M
P/E
1.0×
Fwd P/E
—
Dividend yield
—
F-score
3/9
Altman Z
−2.08
Beneish M
−2.95
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 5 3 5

+8 more TTM periods

ROE
59.74% 31.84% (121.84%) (118.80%)
ROA
28.24% 16.22% (36.66%) (44.08%)
ROIC
(40.56%) (51.58%) 0.00% 0.00%
Return on Tangible Assets
40.44% 23.91% (58.54%) (75.50%)
Average Days of Receivables
99.19 90.99 61.39 68.05
Free Cash Flow per Share
(3.36) (8.23) (8.47) (10.36)
Free Cash Flow
(3.52) (8.61) (8.93) (10.97)
Other line items

Show all line items

Columns are period end dates